The Final Chapter for Danimer Scientific Shareholders

The story of Danimer Scientific, once a celebrated pioneer in bioplastics, has reached its definitive conclusion on the public markets. The company’s journey from a stock market hopeful to a dissolved entity is now complete, following its delisting, a bankruptcy filing, and ultimate absorption into a new corporate parent. For investors, the outcome is a stark one.

A Bankruptcy Filing and Delisting

The company’s operational decline culminated in its removal from the New York Stock Exchange (NYSE) in late 2024. This delisting was triggered by the firm’s market capitalization remaining below the exchange’s minimum requirements for a consecutive 30-day period. Losing its place on the regulated market accelerated the firm’s financial distress.

This was followed by a Chapter 11 bankruptcy protection filing in March of last year. Management pursued this strategic legal move to attempt a court-supervised restructuring of operations and to protect remaining assets.

Should investors sell immediately? Or is it worth buying Danimer Scientific?

Absorption by Teknor Apex Marks the End

The restructuring process concluded not with a revival but with an acquisition. In June 2025, global materials science specialist Teknor Apex took over Danimer Scientific. The deal secured Danimer’s valuable patents and production facilities for the acquirer.

This transaction erased Danimer Scientific as an independent, publicly-traded company. For former equity holders, it signifies a total loss of their investment. While the biodegradable plastics technology continues within Teknor Apex’s portfolio, the original shares are now worthless. The integration of Danimer’s former operations into its new owner’s structure is reported to be fully finalized.